Prevail Therapeutics Inc.
Net SellingPRVL·US·🇺🇸 US
43%buys·57%sells
85 transactions$1.6BTotal buys·6 buys
$0Total sells·8 sells
1818 insiders
Last: Jan 22, 2021
| Date | Insider | Type | Value | |
|---|---|---|---|---|
| Jan 22, 21 | Thompson Peter A | Disposition | - | |
| Jan 22, 21 | GORDON CARL L | Disposition | - | |
| Jan 22, 21 | Nussbaum Ran | Disposition | - | |
| Jan 22, 21 | Sheng Morgan | Disposition | - | |
| Jan 22, 21 | Sheng Morgan | Disposition | - | |
| Jan 22, 21 | Sevigny Jeffrey | Disposition | - | |
| Jan 22, 21 | Sevigny Jeffrey | Disposition | - | |
| Jan 22, 21 | Sevigny Jeffrey | Disposition | - | |
| Jan 22, 21 | Schwartz Kira M. | Disposition | - | |
| Jan 22, 21 | Nader Francois | Disposition | - |
Prevail Therapeutics Inc. (PRVL) has recorded 85 insider transactions from 18 insiders. Total insider buying volume stands at $1.6B, while total selling volume is $0. Overall insider sentiment is bearish (57% sales).
Prevail Therapeutics Inc. (PRVL) has recorded 85 insider operations, including 6 open-market purchases ($1.6B), 8 sales ($0) and 71 other operations (stock option exercises, grants, tax dispositions, donations). The insider sentiment is bearish (57% sales).
Prevail Therapeutics Inc. shows moderate insider activity with 5 active months out of the last 12, typical of a company whose trading windows are concentrated around financial disclosures.
Among the most active insiders are Abeliovich Asa (CEO), Kaplan Brett (CFO) & Minkow Emily (C SUITE), with respectively 10, 9, 8 transactions.
Across all 85 recorded transactions, the breakdown by type is: disposition (31, 36%), exercise (24, 28%), grant (15, 18%), sells (8, 9%), buys (6, 7%).
Data sourced from regulatory filings (SEC Form 4, AMF, BaFin, FI, and other European authorities).
Prevail Therapeutics Inc. has recorded 85 insider operations in total, including 6 open-market purchases ($1.6B), 8 sales ($0) and 71 other operations (stock option exercises, grants, tax dispositions, donations). The most recent transaction was recorded on January 22, 2021.
Insiders at Prevail Therapeutics Inc. are currently net sellers, with 43% purchases and 57% sales across all reported transactions. Total buy volume is $1.6B versus $0 in sales, indicating a bearish insider sentiment.
InsiderLens tracks 18 insiders at Prevail Therapeutics Inc. (PRVL). Abeliovich Asa (CEO, 10 tx), Kaplan Brett (CFO, 9 tx), Minkow Emily (C SUITE, 8 tx). Data is sourced from mandatory regulatory filings for persons with access to privileged information.
The insider signal for PRVL is bearish, based on a 43% buy ratio across 14 buy and sell transactions reported to financial regulators. Transactions from C-suite executives (CEO, CFO) and board members are generally considered the most informative signals.
Insider trading data for Prevail Therapeutics Inc. comes from official regulatory filings: SEC Form 4 (United States), AMF (France), BaFin (Germany), FI (Sweden), and other European financial authorities. These filings are mandatory for directors, officers, and holders of more than 10% of a company's shares. InsiderLens aggregates and normalizes this data for analysis.